Effect of Huachansu Capsule combined with gefitinib targeted therapy on serum CYFRA21-1 and CEA and prognosis in patients with locally advanced NSCLC
Objective To investigate the effect of Huachansu Capsule combined with gefitinib targeted therapy on serum cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA)and prognosis in patients with locally advanced non-small cell lung cancer(NSCLC).Methods A retrospective analysis of 80 patients with locally advanced NSCLC treated at the People's Hospital of Sixian County from January 2021 to January 2023 was performed.They were divided into combination group(n=35)and control group(n=45)according to different treatment methods.The combination group was treated with Huachansu Capsule and gefitinib targeted therapy,while the control group was treated with gefitinib targeted therapy alone.With 28d as one course of treatment,and all patients receive treatment until tumor progression.The differences in serum CYFRA21-1,CEA before and after treatment are measured.At the same time,the incidence rates of treatment-related toxicities and prognosis were recorded.Results The objective response rate(ORR)and disease control rate(DCR)in the combination group were 65.00％and 91.43％,respectively.Compared with the control group's 60.00％and 84.44％,the difference was not statistically significant(x2=0.274,0.8787,P＞0.05).After treatment,serum CYFRA21-1 and CEA levels in the combination group were lower than those in the control group(t=4.016,3.094,P＜0.05).There was no statistically significant difference in the incidence of rash,elevated transaminases,and diarrhea between the two groups(x2=1.055,1.064,0.006,P＞0.05).The one-year recurrence rate in the combination group was significantly lower than that in the control group(8.57％vs.26.67％,x2=4.232,P＜0.05).Conclusion The short-term efficacy of Huachansu capsules combined with gefitinib targeted therapy is comparable to that of single gefitinib targeted therapy,but the combination therapy has advantages over single therapy in reducing serum CYFRA21-1 and CEA levels,and reduce 1-year recurrence rate.
万方数据
维普
